» Articles » PMID: 33809714

Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments

Overview
Journal Cells
Publisher MDPI
Date 2021 Apr 3
PMID 33809714
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Molecular alterations in cancer genes and associated signaling pathways are used to inform new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal antibodies directed at relevant cancer-related proteins have been instrumental in delivering successful treatments of some blood malignancies (e.g., imatinib with chronic myelogenous leukemia (CML)) and solid tumors (e.g., tamoxifen with ER positive breast cancer and trastuzumab for HER2-positive breast cancer). However, inherent limitations such as drug toxicity, as well as acquisition of de novo or acquired mechanisms of resistance, still cause treatment failure. Here we provide an up-to-date review of the successes and limitations of current targeted therapies for cancer treatment and highlight how recent technological advances have provided a new level of understanding of the molecular complexity underpinning resistance to cancer therapies. We also raise three basic questions concerning cancer drug discovery based on molecular markers and alterations of selected signaling pathways, and further discuss how combination therapies may become the preferable approach over monotherapy for cancer treatments. Finally, we consider novel therapeutic developments that may complement drug delivery and significantly improve clinical response and outcomes of cancer patients.

Citing Articles

Atomic Force Microscopy: A Versatile Tool in Cancer Research.

Persano F, Parodi A, Pallaeva T, Kolesova E, Zamyatnin Jr A, Pokrovsky V Cancers (Basel). 2025; 17(5).

PMID: 40075706 PMC: 11899184. DOI: 10.3390/cancers17050858.


The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers.

Molefi T, Mabonga L, Hull R, Mwazha A, Sebitloane M, Dlamini Z Cells. 2025; 14(5).

PMID: 40072110 PMC: 11898822. DOI: 10.3390/cells14050382.


Protein Arginine Methyltransferase 1: A Multi-Purpose Player in the Development of Cancer and Metabolic Disease.

de Korte D, Hoekstra M Biomolecules. 2025; 15(2).

PMID: 40001488 PMC: 11852820. DOI: 10.3390/biom15020185.


Role of Cell Adhesion in Cancer Metastasis Formation: A Review.

Burcik D, Macko J, Podrojkova N, Demeterova J, Stano M, Orinak A ACS Omega. 2025; 10(6):5193-5213.

PMID: 39989825 PMC: 11840620. DOI: 10.1021/acsomega.4c08140.


Identifying Sex Differences in Lung Adenocarcinoma Using Multi-Omics Integrative Protein Signaling Networks.

Chen C, Saha E, Fischer J, Ben Guebila M, Fanfani V, Shutta K bioRxiv. 2025; .

PMID: 39975108 PMC: 11838606. DOI: 10.1101/2025.02.03.636354.


References
1.
Maehama T, Dixon J . The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998; 273(22):13375-8. DOI: 10.1074/jbc.273.22.13375. View

2.
Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

3.
Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho J . FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019; 30(8):1289-1297. DOI: 10.1093/annonc/mdz177. View

4.
Kettner N, Vijayaraghavan S, Guray Durak M, Bui T, Kohansal M, Ha M . Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. Clin Cancer Res. 2019; 25(13):3996-4013. PMC: 6606366. DOI: 10.1158/1078-0432.CCR-18-3274. View

5.
Modi S, Saura C, Yamashita T, Park Y, Kim S, Tamura K . Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2019; 382(7):610-621. PMC: 7458671. DOI: 10.1056/NEJMoa1914510. View